Biogen and Ionis have revealed the first clinical results with tau-targeting Alzheimer's drug candidate diranersen, showing ...
Zacks Investment Research on MSN
Ionis begins dosing in phase I/II Dravet syndrome study
Ionis Pharmaceuticals IONS announced that it has dosed the first patient in the phase I/II ASCEND study, which is evaluating ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people living ...
The open-label trial enrolled patients aged between two and 12 years who have a clinical diagnosis of Dravet syndrome.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study ...
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are ...
The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of ...
Shares in AstraZeneca were trading down more than 8% this morning after it revealed that its transthyretin amyloidosis (ATTR) ...
The drugmakers said the drug didn’t meet its primary objective in a Phase 3 trial when treating a rare type of heart disease.
Ionis Pharmaceuticals (IONS) stock falls as Roche (RHHBY) discontinues two experimental therapies for Huntington’s disease ...
Learn more about whether Ionis Pharmaceuticals, Inc. or Nurix Therapeutics, Inc. is a better investment based on AAII's A+ ...
Learn more about whether Ionis Pharmaceuticals, Inc. or Arcus Biosciences, Inc. is a better investment based on AAII's A+ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results